Sanofi and Regeneron to expand cemiplimab and dupilumab development

Sanofi and Regeneron Pharmaceuticals has announced plans to accelerate and expand investment for the clinical development of two innovative therapies.

The move will see the companies increase their investment in the development of the compound cemiplimab to $1.64 billion (GBP 1.21 billion), an increase of approximately $1 billion over the initial 2015 agreement.

Cemiplimab is being studied as a monotherapy and in combination with other therapies across a wide range of cancers, including advanced skin cancer, non-small cell lung cancer, cervical cancer and lymphomas. US and EU regulatory applications for the drug in advanced cutaneous squamous cell carcinoma are expected in the first quarter of 2018.

Additional investments are also being made in the development of dupilumab, which will help to accelerate planned new studies of the drug in chronic obstructive pulmonary disease (COPD), peanut allergies and grass allergies, as well as in patients who have multiple allergic conditions.

Finally, the companies have committed to accelerate and expand the development of REGN3500, an IL-33 antibody for the treatment of atopic dermatitis, asthma and COPD.

Dr Elias Zerhouni, global head of research and development at Sanofi, said: "The ongoing collaboration between Sanofi and Regeneron underscores our commitment to partnering in the development of medicines to treat significant unmet medical needs."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.